Rationale for IL-1beta-targeted therapy to minimize hypoxic-ischemic encephalopathy.
Wanderer
A A
AA
Department of Pediatrics, Allergy and Clinical Immunology, University of Colorado Health Sciences Center, Denver, USA. aw@aacmt.com
D000138:Acidosis / Q000276:immunology / Q000503:physiopathology; D002352:Carrier Proteins / Q000502:physiology; D005315:Fetal Diseases / Q000276:immunology* / Q000503:physiopathology; D006801:Humans; D020925:Hypoxia-Ischemia, Brain / Q000276:immunology* / Q000503:physiopathology; D007231:Infant, Newborn; D007249:Inflammation / Q000276:immunology; D053583:Interleukin-1beta / Q000378:metabolism*; D000071199:NLR Family, Pyrin Domain-Containing 3 Protein
D002352:Carrier Proteins; D053583:Interleukin-1beta; D000071199:NLR Family, Pyrin Domain-Containing 3 Protein; C453881:NLRP3 protein, human